Peritoneal (Abdominal Mesothelioma)
Brain Metastases With Malignant Peritoneal Mesothelioma: Never Reported Before
Cureus 2023 August 19 [Link] Darshan Lal, Merissa Misiura, Waqas Adeel, Rizwan Tariq Abstract Malignant mesothelioma is a very rare diagnosis. Malignant mesotheliomas arise from surface linings of pleura, peritoneal cavity, or tunica vaginalis and pericardium with pleural malignant mesotheliomas being the most common. The incidence of brain metastases has been very low with malignant…
Read MoreZimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature
World Journal of Clinical Cases 2023 August 6 [Link] Xiao-Dong Peng, Zhen-Yu You, Lian-Xiang He, Qi Deng Abstract Background: Malignant peritoneal mesothelioma (MPeM) is a rare cancer with a poor prognosis at advanced stage, and the standard first-line treatment for inoperable patients is chemotherapy. Although combining programmed cell death 1 (PD-1) inhibitors with chemotherapy is…
Read More2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma
Annals of Surgical Oncology 2023 July 23 [Link] Vahan Kepenekian, Olivia Sgarbura, Frederic Marchal, Laurent Villeneuve, Shigeki Kusamura, Marcello Deraco Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive primary peritoneal disease, with recommended treatment, in eligible patients, of a combination of complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). As…
Read MoreCisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform
Scientific Reports 2023 July 19 [Link] Steven D Forsythe, Richard A Erali, Nicholas Edenhoffer, William Meeker, Nadeem Wajih, Cecilia R Schaaf, Preston Laney, Cristian D Vanezuela, Wencheng Li, Edward A Levine, Shay Soker, Konstantinos I Votanopoulos Abstract Peritoneal mesothelioma (PM) is a rare malignancy with poor prognosis, representing about 10-15% of all mesothelioma cases. Herein…
Read MoreMolecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies
ESMO Open 2023 July 13 [Link] M V Dietz, J P van Kooten, M S Paats, J G V J Aerts, C Verhoef, E V E Madsen, H J Dubbink, J H von der Thüsen Abstract Background: Peritoneal mesothelioma (PeM) is a rare malignancy with a poor prognosis. Currently there is a lack of effective…
Read MoreAdjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial
Journal for Immunotherapy of Cancer 2023 August [Link] Michelle V Dietz, Katrien L A Quintelier, Job P van Kooten, Nadine L de Boer, Madelief Vink, Alexandra R M Brandt-Kerkhof, Cornelis Verhoef, Yvan Saeys, Joachim G J V Aerts, Marcella Willemsen, Sofie Van Gassen, Eva V E Madsen Abstract Background: Malignant peritoneal mesothelioma (MPM) is an…
Read MorePeritoneal papillary mesothelioma in situ: BAP1 mutation with indolent behavior for 15 years
Virchows Archive 2023 July 10 [Link] Nikola Vitlarov, E Burtscher, E Pfeiffenberger, A Wahl, V Hodja, Z Jasarevic, K Kashofer, F A Offner Abstract Papillary mesothelioma in situ (PMIS) is a rare and enigmatic disease. Most instances manifest as lesions of the peritoneal serosa. The pathogenesis and behavior of peritoneal PMIS are still poorly understood,…
Read MoreGenetic Pathways in Peritoneal Mesothelioma Tumorigenesis
Cancer Genomics and Proteomics 2023 Jul-Aug [Link] Ioannis Panagopoulos, Kristin Andersen, Marta Brunetti, Ludmila Gorunova, Ben Davidson, Marius Lund-Iversen, Francesca Micci, Sverre Heim Abstract Background/aim: Mesotheliomas are tumors similar to, and probably derived from, mesothelial cells. They carry acquired chromosomal rearrangements, deletions affecting CDKN2A, pathogenetic polymorphisms in NF2, and fusion genes which often contain the…
Read MoreHigh-Risk Peritoneal Mesothelioma: Does Metronomic Chemotherapy Have a Role?
Indian Journal of Surgical Oncology 2023 June [Link] Praveen Kammar, Niharika Garach, Aditi Bhatt, Jay Anam, Vashisth Maniar, Adwaita Gore, Sanket Mehta Abstract Objective: To evaluate the feasibility, tolerance, and efficacy of OMCT (oral metronomic chemotherapy) after CRS + HIPEC for peritoneal mesothelioma in patients with poor prognostic factors: PCI > 20, incomplete CRS, poor…
Read MoreSynchronous Pleural and Peritoneal Mesothelioma: a Case Report and Narrative Review
Indian Journal of Surgical Oncology 2023 June [Link] Miguel Enrique Alberto Vilchez, Eva Pachmayr, Alexander Arnold, Safak Gül-Klein, Andreas Brandl, Beate Rau Abstract Malignant mesotheliomas most often affect the pleura and tend to spread locally within the originating cavity. Mesotheliomas are already rare diseases, and cases with synchronous pleural and peritoneal involvement are scarce in…
Read More